Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 20 02:27PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.66 Insider Own36.70% Shs Outstand38.11M Perf Week-3.72%
Market Cap28.20M Forward P/E- EPS next Y-1.07 Insider Trans0.00% Shs Float24.14M Perf Month-6.38%
Income-63.03M PEG- EPS next Q-0.49 Inst Own31.69% Short Float8.22% Perf Quarter-36.24%
Sales11.32M P/S2.49 EPS this Y21.58% Inst Trans-0.17% Short Ratio8.65 Perf Half Y-28.88%
Book/sh2.73 P/B0.27 EPS next Y25.20% ROA-36.11% Short Interest1.98M Perf Year-48.99%
Cash/sh2.40 P/C0.31 EPS next 5Y- ROE-48.14% 52W Range0.73 - 1.68 Perf YTD-33.96%
Dividend Est.- P/FCF- EPS past 5Y-40.84% ROI-52.16% 52W High-55.98% Beta0.93
Dividend TTM- Quick Ratio5.68 Sales past 5Y169.01% Gross Margin76.99% 52W Low1.32% ATR (14)0.04
Dividend Ex-Date- Current Ratio5.68 EPS Y/Y TTM23.40% Oper. Margin-661.19% RSI (14)32.37 Volatility3.31% 3.76%
Employees100 Debt/Eq0.19 Sales Y/Y TTM67.96% Profit Margin-556.59% Recom3.00 Target Price3.35
Option/ShortNo / Yes LT Debt/Eq0.16 EPS Q/Q36.97% Payout- Rel Volume0.87 Prev Close0.74
Sales Surprise154.17% EPS Surprise45.10% Sales Q/Q188.83% EarningsMay 14 AMC Avg Volume229.35K Price0.74
SMA20-2.83% SMA50-24.01% SMA200-29.75% Trades Volume154,076 Change0.63%
Date Action Analyst Rating Change Price Target Change
Jan-06-22Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-02-21Initiated SVB Leerink Outperform $36
Mar-02-21Initiated Stifel Buy $40
Mar-02-21Initiated Morgan Stanley Overweight $45
Mar-02-21Initiated Guggenheim Buy $42
May-24-24 06:13AM
May-15-24 03:00PM
10:54PM Loading…
May-14-24 10:54PM
Mar-21-24 10:53PM
Feb-27-24 07:00AM
Dec-21-23 07:30AM
Dec-05-23 07:00AM
Nov-09-23 04:05PM
Nov-07-23 07:00AM
Oct-24-23 12:30PM
10:30AM Loading…
Oct-23-23 10:30AM
Oct-18-23 07:00AM
Oct-17-23 07:00AM
Oct-16-23 07:00AM
Sep-28-23 07:00AM
Sep-12-23 08:05AM
Sep-05-23 04:15PM
Aug-09-23 06:10AM
Aug-07-23 04:10PM
Aug-03-23 07:30AM
Jul-31-23 05:27PM
Jun-13-23 11:22AM
May-30-23 08:00AM
May-25-23 05:05PM
May-11-23 04:05PM
10:00AM Loading…
Apr-26-23 10:00AM
Apr-11-23 07:41AM
Mar-30-23 01:16PM
Mar-29-23 04:15PM
Mar-14-23 04:30PM
Feb-28-23 08:00AM
Feb-01-23 08:00AM
Jan-04-23 09:31AM
Dec-14-22 04:43PM
Nov-10-22 04:05PM
Nov-07-22 08:00AM
Nov-02-22 07:20AM
Nov-01-22 10:01AM
Sep-09-22 12:08PM
Aug-31-22 07:30AM
Aug-25-22 12:23PM
Aug-10-22 04:05PM
Jul-22-22 08:44AM
Jun-10-22 07:21AM
May-27-22 08:00AM
May-26-22 06:52AM
May-13-22 08:28AM
May-12-22 04:05PM
May-11-22 07:32AM
Apr-07-22 08:00AM
Mar-30-22 04:05PM
Mar-08-22 04:30PM
Feb-12-22 06:30AM
Feb-02-22 08:00AM
Jan-27-22 01:43PM
Jan-06-22 08:00AM
Dec-17-21 06:14AM
Dec-16-21 08:00AM
Dec-06-21 04:29PM
Dec-02-21 06:00AM
Nov-19-21 08:00AM
Nov-12-21 07:00AM
Nov-09-21 04:05AM
Nov-08-21 08:00AM
Nov-03-21 08:00AM
Oct-01-21 08:00AM
Sep-08-21 07:30AM
Sep-02-21 08:00AM
Aug-27-21 05:55AM
Aug-26-21 04:05PM
Aug-16-21 06:26AM
Aug-12-21 04:05PM
Aug-02-21 04:32PM
Jul-20-21 12:42AM
Jun-22-21 08:16PM
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quinn William P.Chief Financial OfficerDec 12 '23Buy0.957,5007,12536,272Dec 13 01:40 PM
Quinn William P.Chief Financial OfficerDec 06 '23Buy0.782,5001,95528,772Dec 13 01:40 PM
ENGLEMAN EDGARDirectorNov 30 '23Sale0.86123,079105,614251,522Dec 01 12:31 PM
ENGLEMAN EDGARDirectorNov 29 '23Sale0.9125,80523,379266,456Dec 01 12:31 PM
Vivo Capital VIII, LLC10% OwnerNov 21 '23Sale0.903,4003,060111,662Nov 22 06:51 PM
ENGLEMAN EDGARDirectorNov 21 '23Sale0.901,9431,751269,587Nov 22 07:45 PM
Vivo Capital VIII, LLC10% OwnerNov 20 '23Sale0.9254,70050,324113,119Nov 20 09:09 PM
ENGLEMAN EDGARDirectorNov 20 '23Sale0.9231,25728,756269,823Nov 20 09:31 PM
Vivo Capital VIII, LLC10% OwnerNov 17 '23Sale0.9316,35415,209136,562Nov 20 09:09 PM
ENGLEMAN EDGARDirectorNov 17 '23Sale0.939,3458,691273,615Nov 20 09:31 PM
Vivo Capital VIII, LLC10% OwnerNov 16 '23Sale0.9615,00014,400143,571Nov 20 09:09 PM
ENGLEMAN EDGARDirectorNov 16 '23Sale0.968,5718,228274,749Nov 20 09:31 PM